EMBC vs TMDX
EMBC: A dedicated diabetes care company specializing in insulin delivery systems and pen needles for millions of users worldwide. TMDX: TransMedics commercializes the only FDA-approved portable warm perfusion platform for multi-organ transplantation, replacing cold storage to dramatically increase donor organ utilization and post-transplant outcomes.
Side-by-side fundamentals
| Metric | EMBC | TMDX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.25 | $71.20 | |
| Market cap as of 2026-07-23 | $193M | $2.5B | |
| P/E as of 2026-07-23 | 1.72 | 14.43 | EMBC lower |
| PEG as of 2026-07-23 | -0.17 | 0.08 | EMBC lower |
| Net margin as of 2026-07-23 | +10.7% | +27.0% | TMDX higher |
| Gross margin as of 2026-07-23 | +61.9% | +59.1% | EMBC higher |
| Operating margin as of 2026-07-23 | +25.8% | +14.8% | EMBC higher |
| ROE as of 2026-07-23 | +6.1% | +41.9% | TMDX higher |
| ROA as of 2026-07-23 | +10.3% | +15.8% | TMDX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.73 | EMBC lower |
| Revenue growth (YoY) as of 2026-07-23 | -3.4% | +30.2% | TMDX higher |
| Revenue CAGR (3y) SEC XBRL | -1.5% | +86.4% | TMDX higher |
| Dividend yield as of 2026-07-23 | +1.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | 0 | EMBC higher |
| Beta as of 2026-07-23 | 0.84 | 1.94 | |
| 1-year return as of 2026-07-22 close | -67.2% | -32.6% | TMDX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.